Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1863-1870

  Yang, Linlin ^a   Chen, Yuan ^a   Cui, Tiantian ^a   Knösel, Thomas ^a   Zhang, Qing ^a   Albring, Kai Frederik ^a   Huber, Otmar ^a   Petersen, Iver ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DESMOPLAKIN; GEMCITABINE; LYMPHOID ENHANCER FACTOR 1; MATRIX METALLOPROTEINASE 14; PLAKOGLOBIN; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CELL PROLIFERATION; DNA METHYLATION; DOWN REGULATION; DRUG SENSITIVITY; EPIGENETICS; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84867287011     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs226     Document Type: Article

References (43)

1. Jemal, A. et al. (2011) Global cancer statistics. CA Cancer J Clin., 61, 69-90.
2. Pfister, D.G. et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol., 22, 330-353.
3. Nguyen, D.X. et al. (2009) Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer, 9, 274-284.
4. Behrens, J. (1999) Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev., 18, 15-30.
5. Thomason, H.A. et al. (2010) Desmosomes: adhesive strength and signalling in health and disease. Biochem. J., 429, 419-433.
6. Huber, O. (2003) Structure and function of desmosomal proteins and their role in development and disease. Cell. Mol. Life Sci., 60, 1872-1890.
7. Allen, E. et al. (1996) Mice expressing a mutant desmosomal cadherin exhibit abnormalities in desmosomes, proliferation, and epidermal differentiation. J. Cell Biol., 133, 1367-1382.
8. Wan, H. et al. (2007) Increased keratinocyte proliferation initiated through downregulation of desmoplakin by RNA interference. Exp. Cell Res., 313, 2336-2344.
9. Rickelt, S. et al. (2009) Upregulation of plakophilin-2 and its acquisition to adherens junctions identifies a novel molecular ensemble of cell-cell-attachment characteristic for transformed mesenchymal cells. Int. J. Cancer, 125, 2036-2048.
10. Leung, C.L. et al. (2002) Plakins: a family of versatile cytolinker proteins. Trends Cell Biol., 12, 37-45.
11. Delva, E. et al. (2009)) The desmosome. Cold Spring Harb. Perspect. Biol., 1, a002543.
12. Angst, B.D. et al. (1990) Desmoplakin II expression is not restricted to stratified epithelia. J. Cell. Sci., 97 (Pt 2), 247-257.
13. Jonkman, M.F. et al. (2005) Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am. J. Hum. Genet., 77, 653-660.
14. Kowalczyk, A.P. et al. (1997) The amino-terminal domain of desmoplakin binds to plakoglobin and clusters desmosomal cadherin-plakoglobin complexes. J. Cell Biol., 139, 773-784.
15. Garrod, D. et al. (2008) Desmosome structure, composition and function. Biochim. Biophys. Acta, 1778, 572-587.
16. Chun, M.G. et al. (2010) Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet., 6, e1001120.
17. Oshiro, M.M. et al. (2005) Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res., 7, R669-R680.
18. Papagerakis, S. et al. (2009) Altered desmoplakin expression at transcriptional and protein levels provides prognostic information in human oropharyngeal cancer. Hum. Pathol., 40, 1320-1329.
19. Alazawi, W.O. et al. (2003) Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix. Virchows Arch., 443, 51-56.
20. Cui, T. et al. (2011) DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br. J. Cancer, 104, 1013-1019.
21. Hamidov, Z. et al. (2011) Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J. Clin. Pathol., 64, 990-994.
22. Chen, Y. et al. (2007) Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int. J. Cancer, 121, 1021-1027.
23. Chen, Y. et al. (2007) Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J. Pathol., 211, 431-438.
24. Hampf, M. et al. (2006) A protocol for combined Photinus and Renilla luciferase quantification compatible with protein assays. Anal. Biochem., 356, 94-99.
25. Koeser, J. et al. (2003) De novo formation of desmosomes in cultured cells upon transfection of genes encoding specific desmosomal components. Exp. Cell Res., 285, 114-130.
26. Garcia-Gras, E. et al. (2006) Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J. Clin. Invest., 116, 2012-2021.
27. Simcha, I. et al. (1996) Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J. Cell Biol., 133, 199-209.
28. Schiller, J.H. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med., 346, 92-98.
29. Zembutsu, H. et al. (2003) Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int. J. Oncol., 23, 29-39.
30. Kakiuchi, S. et al. (2004) Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum. Mol. Genet., 13, 3029-3043.
31. Davies, E.L. et al. (1999) The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer. Eur. J. Cancer, 35, 902-907.
32. Beaudry, V.G. et al. (2010) Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet., 6, e1001168.
33. Mueller, W.C. et al. (2009) Gene regulation by methylation. Recent Results Cancer Res., 171, 217-239.
34. Jones, P.A. et al. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428.
35. Herman, J.G. et al. (2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med., 349, 2042-2054.
36. Shiina, H. et al. (2005) Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res., 65, 2130-2138.
37. Breault, J.E. et al. (2005) Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin. Cancer Res., 11(2 Pt 1), 557-564.
38. Langer, F. et al. (2005) [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies]. Onkologie, 28 Suppl 1, 1-28.
39. Silvestris, N. et al. (2008) Role of gemcitabine in metastatic breast cancer patients: a short review. Breast, 17, 220-226.
40. Di Marco, M. et al. (2010) Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol. Rep., 23, 1183-1192.
41. Denlinger, C.E. et al. (2004) Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J. Thorac. Cardiovasc. Surg., 128, 740-748.
42. Zhurinsky, J. et al. (2000) Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J. Cell. Sci., 113 (Pt 18), 3127-3139.
43. Winn, R.A. et al. (2002) gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene, 21, 7497-7506.